-
-
-
-
-
-
-
ChromaDex (CDXC) Receives Exclusive U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia
-
-
-
-
-
-
-
Qiagen (QGEN) to discontinue NeuMoDx integrated PCR testing system
-
-
-
-
-
-
-
Eli Lilly & Co. (LLY) on Watch After FDA Posts Documents Ahead of Panel Meeting for AD Drug
-
-
-
-
-
-
-
Moderna's (MRNA) mRNA-3705 Selected by the FDA for START Pilot Program
-
-
-
-
-
-
-
Amgen (AMGN) Reports Positive Phase 3 Results for UPLIZNA
-
-
-
-
-
-
-
I-Mab Biopharma (IMAB) Collaborates with Bristol Myers Squibb (BMY) to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
-
-
-
-
-
-
-
Gilead Sciences' (GILD) Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
-
67,340 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.